Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.

Publication Type:

Journal Article

Source:

The Lancet infectious diseases, Volume 11, Issue 4, p.284-92 (2011)

Keywords:

2011, Administration, Oral, Adolescent, Adult, Aged, Antiviral Agents, Benzimidazoles, Canada, Center-Authored Paper, Chemoprevention, Cytomegalovirus Infections, Double-Blind Method, Europe, Female, Humans, Male, Middle Aged, Placebos, Ribonucleosides, Stem Cell Transplantation, transplantation, Treatment Outcome, United States, Vaccine and Infectious Disease Division, Young Adult

Abstract:

Available drugs against cytomegalovirus have adverse effects that compromise their prophylactic use in recipients of allogeneic stem-cell transplants. We assessed the safety, tolerability, and antiviral activity of oral maribavir in such patients.